Nov 30, 2022
CAMBRIDGE, Mass. , Nov. 30, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, announced today the pricing of an underwritten public offering
Nov 30, 2022
CAMBRIDGE, Mass. , Nov. 30, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced that it has commenced an underwritten public
Nov 12, 2022
Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts have an ongoing attack-free interval through latest follow-up First three patients treated have an ongoing attack-free interval of 5.5 – 10.6 months
Nov 05, 2022
Data presented in late-breaking oral presentation demonstrated deep and consistent TTR reduction following a single dose of NTLA-2001 in patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM) Greater than 90% mean serum TTR reductions after a single dose of NTLA-2001 were sustained at both
Sep 26, 2022
CAMBRIDGE, Mass. , Sept. 26, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that members of its management team will be